Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
AstraZeneca
Express Scripts
Dow
Johnson and Johnson

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

NOCDURNA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Nocdurna, and what generic alternatives are available?

Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and nineteen patent family members in thirty-three countries.

The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

Drug patent expirations by year for NOCDURNA
Drug Prices for NOCDURNA

See drug prices for NOCDURNA

Recent Clinical Trials for NOCDURNA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2

See all NOCDURNA clinical trials

Recent Litigation for NOCDURNA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Ferring B v. v. Allergan Inc.2012-04-05

See all NOCDURNA litigation

US Patents and Regulatory Information for NOCDURNA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NOCDURNA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2712622 LUC00015 Luxembourg   Start Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
2712622 122017000006 Germany   Start Trial PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249 2019C/520 Belgium   Start Trial PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 PA2017001 Lithuania   Start Trial PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
3225249 CA 2019 00023 Denmark   Start Trial PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Express Scripts
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.